IBB Stock UPDATES Nasdaq Biotechnology Ishares (IBB) 276.55 09/02/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Nasdaq Biotechnology Ishares (IBB) 276.55 $IBB

Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?

Biotech Stock Boom Times Are Back
at The Street - Tue Aug 26, 6:00AM CDT
The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

'Fast Money' Recap: Next Stop, S&P 2,100?
at The Street - Tue Aug 26, 4:00AM CDT
The trading panel looked at banks and the top buy and sell candidates for right now.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.33% Rise
Comtex SmarTrend(R) - Mon Aug 25, 4:07PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

After Yesterday's Rally of 2.33% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Aug 25, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $268.75 to a high of $272.88. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $268.60 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Economic Recovery Doesn't Satisfy Fed as Stocks Soar Higher
at The Street - Thu Aug 21, 10:14AM CDT
Low inflation and slack in the labor market has kept policymakers dovish, leading to strength in U.S. equities and in high-beta sectors.

Nasdaq Composite: What Are You Buying That's Driving New Highs? - Real Time Insight
Zacks Equity Research - ZACKS - Mon Aug 18, 1:04PM CDT
It's not just the big caps attracting all the money

Eased Geopolitical Tensions Have Little Effect on Interest Rates
at The Street - Fri Aug 15, 11:16AM CDT
It seems that no matter what, investors just want a reason to continue buying bonds and pressuring rates lower.

SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 2.17% Gain
Comtex SmarTrend(R) - Wed Aug 13, 3:58PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.61 to a high of $257.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $254.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

iShares Nasdaq Biotechnology Index Rises 2.17% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Wed Aug 13, 3:58PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.61 to a high of $257.59. Yesterday, the shares gained 2.2%, which took the trading range above the 3-day high of $254.75 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

'Fast Money' Recap: Can You Trust This Rally?
at The Street - Tue Aug 12, 4:00AM CDT
The trading panel discussed whether the Federal Reserve is having more of an effect on the markets than geopolitical events.

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.46%
Comtex SmarTrend(R) - Thu Aug 07, 3:57PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $247.35 to a high of $252.94. Yesterday, the shares fell 1.5%, which took the trading range below the 3-day low of $248.83 on volume of 974,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

'Fast Money' Recap: Is Michael Kors Still in Fashion?
at The Street - Tue Aug 05, 4:00AM CDT
The trading panel looked at Michael Kors' earnings, Microsoft, steel stocks and biotechs.

Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.

'Fast Money' Recap: A Game-Changing Twitter Quarter
at The Street - Wed Jul 30, 4:00AM CDT
The trading panel looked at the social media company's earnings, Panera Bread and Spirit Airlines.

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 1.12% Rise
Comtex SmarTrend(R) - Tue Jul 22, 4:11PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $252.27 to a high of $254.88. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $251.52 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

JLL’s Facility Management Push Gets a Useful Nod From Frost

Updated Category News Views 27

A Building Breaks Down Long Before the Earnings Call Notices Facility management is the sort of business that gets ignored until an airport system fails, a data-center cooling unit balks, or a workforce cannot use the building it was told to return to. That is why Frost & Sullivan’s 2026 recognition of JLL deserves more than the usual award-season shrug. It points to an...

Continue Reading
Kyndryl's Gartner Sweep Raises the Execution Bar Again

Updated Category News Views 95

A workplace help-desk ticket may sound dull as drywall, but at a giant enterprise it can become a very expensive little failure. That is why Kyndryl's latest Gartner recognition deserves more than the usual corporate backslapping. The company was named a Leader in Gartner's 2026 Magic Quadrant for Outsourced Digital Workplace Services for a third consecutive year, and...

Continue Reading
Zunyi’s History Tour Carries China’s Story Overseas

Updated Category News Views 196

China’s national story does not travel overseas by accident; it gets carried by visitors, monuments, rail lines, rivers and carefully chosen questions. The Zunyi News and Media Center report follows Tayyab, a Pakistani PhD student in aerospace engineering at Peking University, as he heads from Beijing to Zunyi, Guizhou, carrying a copy of Edgar Snow’s Red Star Over...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 118

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 51

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
A €18 Million Mecca Chandelier Tests Austrian Craft

Updated Category News Views 212

Scale Is Easy to Boast About, Delivery Is Not A 34.1-metre chandelier hanging in Mecca is the sort of job that makes ordinary project talk sound downright silly. Lights of Vienna says it designed, built, tested, shipped and installed this monster for the Grand Mosque's Shamiya area, with a contract value of roughly €18 million. That is a serious piece of work for a...

Continue Reading
Pressure Injury Care Needs More Than Awareness Alone

Updated Category News Views 52

Wet skin does not care how polished the awareness campaign looks. That is the uncomfortable truth sitting underneath Worldwide Pressure Injury Prevention Day, the annual observance held on the third Thursday of November. Pressure injuries remain a stubborn problem across healthcare facilities and home care settings because prevention is not one tidy action; it is a chain...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 245

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading

Top 5 Most Recently Viewed Articles

Science Applications Intl's Earnings Preview: Key Insights Ahead

Updated Category News Views 170

Understanding Science Applications Intl's Earnings Preview Science Applications Intl (NYSE: SAIC) is gearing up for its quarterly earnings announcement. Investors are eager to see how the company performs and whether it meets analysts' expectations. What to Anticipate Analysts project Science Applications Intl will report an earnings per share (EPS) of $2.11, which could...

Continue Reading
Innovative Aerogels Paving the Path for Water Harvesting Solutions

Updated Category News Views 285

Introduction to Atmospheric Water Harvesting The world faces an alarming freshwater crisis, with projections indicating that vast segments of the population are at risk of water scarcity. In response, researchers have innovatively turned to atmospheric water harvesting, particularly highlighting the advancements made by the National University of Singapore (NUS). They...

Continue Reading
Class Action Lawsuit Alert for Tronox Holdings Plc Investors

Updated Category News Views 131

Insights into the Tronox Holdings Class Action Lawsuit Investors in Tronox Holdings Plc (NYSE: TROX) should be aware of a class action lawsuit initiated against the company. This legal action centers around allegations of potential securities fraud and improper business practices by Tronox and some of its leadership. The firm Pomerantz LLP, known for its expertise in...

Continue Reading
Rapport Therapeutics Set to Showcase Innovations in Healthcare

Updated Category News Views 128

Rapport Therapeutics to Attend Major Investor Conferences BOSTON and SAN DIEGO — Rapport Therapeutics, Inc. (Nasdaq: RAPP), a biotechnology firm at the forefront of developing small molecule precision medicines targeting neurological and psychiatric disorders, has expressed its excitement about participating in two notable investor conferences soon. Details of Upcoming...

Continue Reading
Northwestern Mutual Achieves Unmatched Financial Strength Ratings

Updated Category News Views 353

Northwestern Mutual Achieves Elite Financial Ratings for 35 Years For an impressive 35 years, Northwestern Mutual has consistently earned top financial strength ratings from the nation's leading rating agencies. This recognition underscores the company’s commitment to maintaining a robust financial foundation, which plays a crucial role in their ability to serve clients...

Continue Reading